drugset / Trial / NCT05620784

Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

NCT05620784

Phase 3 Recruiting 138 enrolled Northwestern University
RandomizedParallel-groupDouble-blindTreatment

Summary

Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to promote urine production in the post-operative setting and to minimize the impact of fluid absorption during long periods of morcellation. The intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated with the dissemination of HoLEP across North America without evidence to support its routine administration. With increasing surgical efficiency from improvements in laser and morcellator technology, the role of intra-operative furosemide is unknown. This study is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP) with and without IV furosemide. .

Timeline

Start
2023-03-01
Primary completion
2023-06-06
Completion
2024-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Furosemide Other / unclassified 20 mg Intravenous